



IFW/1614

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/594,101
Filing Date	September 25, 2006
First Named Inventor	Cataldo
Art Unit	
Examiner Name	
Attorney Docket Number	22394

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

**USPTO Form 1449;
References****SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Dennis P. Tramaloni
Signature	
Date	02/05/2007

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Dennis P. Tramaloni		
Signature		Date	02/05/2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

281149

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Cataldo, et. al.

Group:

Application No. 10/594,101, filed September 25, 2006
(Case Docket No. 22394)

Examiner:

For: USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT AND PREVENTION OF
BRONCHIAL INFLAMMATORY DISEASES

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
February 5, 2007

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1-A2, B1-B7 and C1-C30 are listed on Form PTO-1449. Documents B1-B7 and C1-C30 are enclosed. Documents A1-A2 are not being submitted because they are US Patents.


Consideration of all the documents cited on Form PTO-1449 is requested.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

Appl. No. 10/594,101
Filed: September 25, 2006

Since the Information Disclosure Statement is submitted before the receipt of the first Office Action on the merits for the above application, it is believed that no fee is due. If a fee is due and owing, please charge to Deposit Account No. 08-2525.

Respectfully submitted,



Attorney for Applicant(s)
Dennis P. Tramaloni
(Reg. No. 28,542)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4475
Telefax: (973) 235-2363

281146



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Application Number	10/594,101
		Filing Date	September 25, 2006
		First Name Inventor	Cataldo
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	22394
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	6,242,455		Grams, et. al.	06-05-2001
	A2	6,110,924		Bosies, et. al.	08-29-2000

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	WO 97/23465			Boehringer Mannheim GMBH	07-03-1997	
	B2	WO01/25217			F. Hoffmann-La Roche AG	04-12-2001	
	B3	WO 98/58915			Boehringer Mannheim GMBH	12-30-1998	
	B4	WO2005/097133			F. Hoffmann-La Roche AG	10-20-2005	
	B5	WO98/58925			Boehringer Mannheim GMBH	12-30-1998	
	B6	WO02/34726			Pfizer Products Inc	05-02-2002	
	B7	WO02/34753			Pfizer Products Inc	05-02-2002	
Examiner Signature	Date Considered						
	/Marcos Sznajdman/		08/05/2008				

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			Application Number	10/594,101	
			Filing Date	September 25, 2006	
			First Name Inventor	Cataldo	
			Group Art Unit		
			Examiner Name		
Sheet	2	Of	2	Attorney Docket Number	22394

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Egeblad, M., and Werb, Z., Nat. Rev. Cancer 2 (2002) 161-174;	
	C2	Overall, C.M., and Lopez-Otin, C., Nat. Rev. Cancer 2 (2002) 657-672	
	C3	Holmbeck, K., et al., Cell 99 (1999) 81-92	
	C4	Vu, T.H., et al., Cell 93 (1998) 411-422	
	C5	Shapiro, S.D., Curr. Opin. Cell Biol. 10 (1998) 602-608	
	C6	Lund, L.R., et al., EMBO J. 18 (1999) 4645-4656	
	C7	Carmeliet, P, Nautre 407 (2000) 249-257	
	C8	Souverain, Jour of Chromo B801 (2004) 141-156	
	C9	Carmeliet, P., et al., Nat. Genet. 17 (1997) 439-444	
	C10	Chang, C., and Werb, D., Trends Cell Biol. 11 (2001) S37-43	
	C11	Manes, S., et al., J. Biol. Chem. 274 (1999) 6935-6945	
	C12	Bergers, G., et al., Nat. Cell Biol. 2 (2000) 737-744	
	C13	Dong, Z., et al., Cell 88 (1997) 801-810	
	C14	Brown, P.D., Med. Oncol. 14 (1997) 1-10	
	C15	Fletcher, L., Nat. Biotechnol. 18 (2000) 1138-1139	
	C16	Drummond, A.H., et al., Ann. N.Y. Acad. Sci. 878 (1999) 228-235	
	C17	Giavazzi, R., et al., Clin. Cancer Res. 4 (1998) 985-992	
	C18	Szelenyi, I., et al., Drugs Today 36 (2000) 313-320	
	C19	Rohatagi, S., et al., J. Clin. Pharmacol. 43 (2003) 365-378	
	C20	Stack, M.S., and Gray, R.D., J. Biol. Chem. 264 (1989) 4277-4281	
	C21	Grams, F., et al., Biol. Chem. 382 (2001) 1277-1285	
	C22	Fabbri, L.M., and Hurd, S.S., Eur. Respir. J. 22 (2003) 1-2	
	C23	Higuchi, T., and Connors, K.A., Advances in Analytical Chemistry and Instrumentation 4 (1965) 117-212	
	C24	Hamelmann, E., et al., Am. J Respir. Crit. Care Med. 156 (1997) 766-775	
	C25	Cataldo, D.D., et al, Am. J. Pathol. 161 (2002) 491-498	
	C26	Yu, Z., and Westerlund, D., Chromatographia 44 (1997) 589-594	
	C27	Chiap, P., et al., Journal of Chromatography B 817 (2005), 109-117	
	C28	Hubert, P., et al., Analytica Chimica Acta 391 (1999) 135-148	
	C29	Hubert, Ph., et al., J Pharm Biomed. Anal. 36 (2004) 579-586	
	C30	Safak, Forum 2003, Band 32	
Examiner Signature	/Marcos Sznaidman/		DATE CONSIDERED 08/05/2008

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation or abstract is attached. 278568

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./